Angiotensin blockade in late autosomal dominant polycystic kidney disease.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  New England Journal of Medicine

• Publication date

  2014-12-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa1402686PMID 25399731PMCID PMC4284824
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).

  2014cited by this paper
• Blood pressure in early autosomal dominant polycystic kidney disease.

  2014cited by this paper
• Autosomal dominant polycystic kidney disease.

  2014cited by this paper
• Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis.

  2013cited by this paper
• Combined angiotensin inhibition for the treatment of diabetic nephropathy.

  2013cited by this paper
• Notice

  2012cited by this paper
• Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

  2012cited by this paper
• Tolvaptan in patients with autosomal dominant polycystic kidney disease.

  2012cited by this paper
• Analysis of baseline parameters in the HALT polycystic kidney disease trials.

  2012cited by this paper
• Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease

  2012cited by this paper
• Everolimus in patients with autosomal dominant polycystic kidney disease.

  2010cited by this paper
• The HALT polycystic kidney disease trials: design and implementation.

  2010cited by this paper
• Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.

  2009cited by this paper
• Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease

  2009cited by this paper
• Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the ReninAngiotensin System on Proteinuria in Renal Disease

  2008cited by this paper
• Telmisartan, ramipril, or both in patients at high risk for vascular events.

  2008cited by this paper
• Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

  2008cited by this paper
• Clinical practice. Autosomal dominant polycystic kidney disease.

  2008cited by this paper
• Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.

  2008cited by this paper
• Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta‐analysis

  2007cited by this paper
• Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease.

  2007cited by this paper
• Shared parameter models for the joint analysis of longitudinal data and event times

  2006cited by this paper
• Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate

  2006cited by this paper
• Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

  2006cited by this paper
• Nonlinear Regression: Seber/Nonlinear Regression

  2005cited by this paper
• The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease.

  2004cited by this paper
• No effect of enalapril on progression in autosomal dominant polycystic kidney disease.

  2003cited by this paper
• Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis

  2003cited by this paper
• Dual renin-angiotensin system blockade at optimal doses for proteinuria.

  2002cited by this paper
• Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease.

  2000cited by this paper
• Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency

  1996cited by this paper
• Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.

  1996cited by this paper
• Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group.

  1995cited by this paper
• Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1.

  1994cited by this paper
• Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease.

  1992cited by this paper
• Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease.

  1991cited by this paper
• The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease.

  1990cited by this paper
• Group sequential procedures: calendar versus information time.

  1989cited by this paper
• The anatomy of the renin-secreting cell in adult polycystic kidney disease.

  1988cited by this paper
• On the regression analysis of multivariate failure time data

  1981cited by this paper

• Evolution of Clinical Trial Design in ADPKD.

  2026cites this paper
• End Point Selection in ADPKD Clinical Trials

  2025cites this paper
• Multisystemic impact of autosomal dominant polycystic kidney disease: A case report highlighting renal, hepatic, and neurological involvement

  2025cites this paper
• New Insights in the Pathophysiology and Treatment of Hypertension in Autosomal Dominant Polycystic Kidney Disease.

  2025cites this paper
• The critical role of the Hippo signaling pathway in renal fibrosis.

  2025cites this paper
• Tolvaptan in Autosomal Dominant Polycystic Kidney Disease (ADPKD): a multicenter real life Italian experience

  2025cites this paper
• Commemorating the National Institute of Diabetes and Digestive and Kidney Diseases' Advances in Kidney Health

  2025cites this paper
• Commemorating the National Institute of Diabetes and Digestive and Kidney Diseases' Advances in Kidney Health: 75 Years of Discovery and Impact.

  2025cites this paper
• Commemorating the National Institute of Diabetes and Digestive and Kidney Diseases' Advances in Kidney Health: 75 Years of Discovery and Impact.

  2025cites this paper
• Overweight Status, Obesity, and Progression to ESKD in Patients with Autosomal Dominant Polycystic Kidney Disease

  2025cites this paper
• Comparative validation of the Mayo Clinic imaging classification and PROPKD score for predicting ADPKD progression across diverse ethnic cohorts

  2025cites this paper
• Cardiovascular Autonomic Control in Normotensive Patients with Autosomal Dominant Polycystic Kidney Disease

  2025cites this paper
• KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

  2025cites this paper
• Integration of Genetics Into the Design and Conduct of Clinical Trials in Nephrology.

  2025cites this paper
• The screening, diagnosis, and management of patients with autosomal dominant polycystic kidney disease: A national consensus statement from Taiwan

  2024cites this paper
• Interventions for preventing the progression of autosomal dominant polycystic kidney disease.

  2024cites this paper
• HYDROchlorothiazide versus placebo to PROTECT polycystic kidney disease patients and improve their quality of life: study protocol and rationale for the HYDRO-PROTECT randomized controlled trial

  2024influential citation
• Genetic Analysis of Severe Polycystic Liver Disease in Japan

  2024cites this paper
• Overview of clinical status, treatment, and long-term outcomes of pediatric autosomal-dominant polycystic kidney disease: a nationwide survey in Taiwan

  2024cites this paper
• Tolvaptan and Autosomal Dominant Polycystic Kidney Disease Progression in Individuals Aged 18-35 Years: A Pooled Database Analysis

  2024cites this paper
• Chronic Kidney Disease-Part 1: Evaluation & Risk Assessment in CKD, Methods to Delay CKD Progression.

  2024cites this paper
• Citrate in autosomal dominant polycystic kidney disease: biomarker or therapeutic agent?

  2024cites this paper
• Treatment of Autosomal Dominant Polycystic Kidney Disease.

  2024cites this paper
• Improved predictions of total kidney volume growth rate in ADPKD using two-parameter least squares fitting

  2024cites this paper
• Effect of Dual RAAS Blockade and Intensive BP Lowering on Risk of End-Stage Kidney Disease and Death in Autosomal Dominant Polycystic Kidney Disease: Long-Term Follow-Up of the HALT-PKD Trials.

  2024cites this paper
• Clinical outcomes of renin angiotensin system inhibitor-based dual antihypertensive regimens in chronic kidney disease: a network meta-analysis

  2023cites this paper
• Management of Hypertension and Associated Cardiovascular Disease in Autosomal Dominant Polycystic Kidney Disease.

  2023cites this paper
• A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

  2023cites this paper
• The Efficacy, the Treatment Response and the Aquaretic Effects of a Three-Year Tolvaptan Regimen in Polycystic Kidney Disease Patients

  2023cites this paper
• Autosomal dominant and autosomal recessive polycystic kidney disease: hypertension and secondary cardiovascular effect in children

  2023cites this paper
• Secular Trend in GFR Decline in Non-Dialysis CKD Based on Observational Data From Standard of Care Arms Of Trials.

  2023cites this paper
• Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies

  2023cites this paper
• Nonpharmacological Management of Autosomal Dominant Polycystic Kidney Disease.

  2023cites this paper
• Patchouli alcohol against renal fibrosis of spontaneously hypertensive rats via Ras/Raf-1/ERK1/2 signalling pathway.

  2023cites this paper
• Drug Development in Autosomal Dominant Polycystic Kidney Disease: Opportunities and Challenges.

  2023cites this paper
• The effects of the renin–angiotensin–aldosterone system blockers on serum ischemia-modified albumin levels in autosomal dominant polycystic kidney disease

  2022cites this paper
• Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD

  2022cites this paper
• The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD

  2022cites this paper
• Poliquistosis renal autosómica dominante: ¿quiénes se benefician del tratamiento con tolvaptán? Estado del arte

  2022cites this paper
• Consensus document on autosomal dominant polycystic kindey disease from the Spanish Working Group on Inherited Kindey Diseases. Review 2020.

  2022cites this paper
• Kynurenines in polycystic kidney disease

  2022cites this paper
• Practical Issues in the Management of Polycystic Kidney Disease: Blood Pressure and Water Balance

  2022cites this paper
• Endocannabinoid System in Polycystic Kidney Disease

  2022cites this paper
• Dietary Aspects and Drug-Related Side Effects in Autosomal Dominant Polycystic Kidney Disease Progression

  2022cites this paper
• Autosomal Dominant Polycystic Kidney Disease: From Pathophysiology of Cystogenesis to Advances in the Treatment

  2022cites this paper
• A Systematic Review of Reported Outcomes in ADPKD Studies

  2022influential citation
• [Cardiovascular disorders in autosomal dominant polycystic kidney disease].

  2021cites this paper
• Was ist gesichert in der Therapie der autosomal-dominanten polyzystischen Nierenerkrankung?

  2021cites this paper
• Effect of Early and Delayed Commencement of Paricalcitol in Combination with Enalapril on the Progression of Experimental Polycystic Kidney Disease

  2021cites this paper
• Autosomal-dominante polyzystische NierenerkrankungManagement im Kindes- und Jugendalter

  2021cites this paper
• OP-NDTJ200151 1828..1836

  2021cites this paper
• Blockierung des Renin-Angiotensin-Aldosteron-Systems

  2021cites this paper
• Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies

  2021cites this paper
• The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial

  2021cites this paper
• Trends in Adaptive Design Methods in Dialysis Clinical Trials: A Systematic Review

  2021cites this paper
• Insights Into the Molecular Mechanisms of Polycystic Kidney Diseases

  2021cites this paper
• Systematic Review and Meta-Analysis of Renin–Angiotensin–Aldosterone System Blocker Effects on the Development of Cardiovascular Disease in Patients With Chronic Kidney Disease

  2021cites this paper
• Emerging non-pharmacological interventions in ADPKD: an update on dietary advices for clinical practice

  2021cites this paper
• Developing a patient-centred tool for pain measurement and evaluation in autosomal dominant polycystic kidney disease

  2021cites this paper
• Cardiac Involvement in Autosomal Dominant Polycystic Kidney Disease

  2021cites this paper
• The perioperative management of simultaneous bilateral nephrectomy with renal transplantation: a case series

  2021cites this paper
• PKD1 Compared With PKD2 Genotype and Cardiac Hospitalizations in the Halt Progression of Polycystic Kidney Disease Studies

  2021cites this paper
• Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Studies

  2021influential citation
• Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression

  2021cites this paper
• Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype.

  2021cites this paper
• Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD).

  2021cites this paper
• Documento de consenso de poliquistosis renal autosómica dominante del grupo de trabajo de enfermedades hereditarias de la Sociedad Española de Nefrología. Revisión 2020

  2021cites this paper
• Impact of early glomerular filtration rate decline in response to antihypertensive treatment on risk of end-stage kidney disease and cardiovascular outcomes: a systematic review and meta-analysis

  2021cites this paper
• Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease

  2021cites this paper
• Metabolic Reprogramming and Reconstruction: Integration of Experimental and Computational Studies to Set the Path Forward in ADPKD

  2021cites this paper
• ‘A sword of Damocles’: patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study

  2020cites this paper
• Recognizing and treating autosomal dominant polycystic kidney disease.

  2020influential citation
• Efficacy and Safety of Naproxen for Acute Pain.

  2020cites this paper
• The importance of the number of antihypertensives in the progression of autosomal dominant polycystic kidney disease.

  2020cites this paper
• Effect of Renin-Angiotensin-Aldosterone System Blockade on Long-Term Outcomes in Postacute Kidney Injury Patients With Hypertension.

  2020cites this paper
• Curcumin therapy to treat vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease: Design and baseline characteristics of participants

  2020cites this paper
• Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease.

  2020cites this paper
• KIM-1 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease: HALT-PKD Results

  2020cites this paper
• The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD.

  2020cites this paper
• Serum Uric Acid and Progression of Autosomal Dominant Polycystic Kidney Disease: Results from the HALT PKD Trials.

  2020cites this paper
• Mineral bone disease in autosomal dominant polycystic kidney disease.

  2020cites this paper
• Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study

  2020cites this paper
• Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review.

  2020cites this paper
• Advances in Autosomal Dominant Polycystic Kidney Disease: A Clinical Review

  2020cites this paper
• STAT signaling in polycystic kidney disease.

  2020cites this paper
• Estimating COVID-19 Case Fatality Rate in the Middle of the Outbreak: Deadlier than Previously Estimated

  2020cites this paper
• Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

  2020cites this paper
• Kidney Biomarkers of Injury and Repair as Predictors of Contrast-Associated AKI: A Substudy of the PRESERVE Trial.

  2020cites this paper
• Is aberrant CD8+ T cell activation by hypertension associated with cardiac injury in severe cases of COVID-19?

  2020cites this paper
• Update and review of adult polycystic kidney disease.

  2020cites this paper
• ALG9 Mutation Carriers Develop Kidney and Liver Cysts.

  2019cites this paper
• [Modern approaches to conservative therapy of polycystic kidney disease].

  2019cites this paper
• Primary prevention of cardiovascular disease events with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with autosomal dominant polycystic kidney disease on dialysis—a nationwide cohort study

  2019cites this paper
• Presymptomatic Screening for Intracranial Aneurysms in Patients with Autosomal Dominant Polycystic Kidney Disease.

  2019cites this paper
• ADPedKD: A Global Online Platform on the Management of Children With ADPKD

  2019cites this paper
• The pathobiology of polycystic kidney disease from a metabolic viewpoint

  2019cites this paper
• GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.

  2019cites this paper
• Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis

  2019cites this paper
• Genetische Nierenerkrankungen

  2019cites this paper
• The management of polycystic liver disease by tolvaptan

  2019cites this paper